Cite
Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.
MLA
Magaret, Amalia S., et al. “Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.” Annals of Internal Medicine, vol. 173, no. 7, Oct. 2020, pp. 576–77. EBSCOhost, https://doi.org/10.7326/M20-2933.
APA
Magaret, A. S., Jacob, S. T., Halloran, M. E., Guthrie, K. A., Magaret, C. A., Johnston, C., Simon, N. R., & Wald, A. (2020). Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions. Annals of Internal Medicine, 173(7), 576–577. https://doi.org/10.7326/M20-2933
Chicago
Magaret, Amalia S., Shevin T. Jacob, M. Elizabeth Halloran, Katherine A. Guthrie, Craig A. Magaret, Christine Johnston, Noah R. Simon, and Anna Wald. 2020. “Multigroup, Adaptively Randomized Trials Are Advantageous for Comparing Coronavirus Disease 2019 (COVID-19) Interventions.” Annals of Internal Medicine 173 (7): 576–77. doi:10.7326/M20-2933.